

At Page 67, line 14, after "3'," add --(SEQ ID NO:82)--.

ADD THE FOLLOWING CLAIM:

44. A composition, comprising:

(a) an antibody produced by the cell line deposited as ATCC HB11423; and
(b) a pharmaceutically acceptable carrier, wherein said antibody is present in said composition in an amount effective to inhibit a T-cell mediated immune response.

REMARKS

The specification has been amended in accordance with the Examiner's helpful suggestions with respect to the Appendix, the sequence identifiers, and the trademarks. Page 12 has been amended in order to state that the deposited strain is being maintained under the terms of the Budapest Treaty, and that it will be made available to a patent office signatory to the Budapest Treaty. Such amendment to Page 12 is being made in response to the rejection under 35 U.S.C. 112, first paragraph.

Claim 44 has been added in order to define a specific composition in accordance with the present invention.

Claims 30-32, 35-40, and 43 stand rejected under 35 U.S.C. 102(b) as being anticipated by Xia, et al.

Claims 30-43 stand rejected under 35 U.S.C. 103 as being unpatentable over Xia, et al. in view of Queen, et al. or Newman, et al. and in further view of Guckel, et al. or Bromberg, et al. or Hafler, et al. or Chavin, et al. or Faustman.

These rejections are respectfully traversed.